STOCK TITAN

Tenaya Therapeutics (TNYA) holder files to sell 1,408,910 Rule 144 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A Tenaya Therapeutics stockholder filed a notice of proposed sale of 1,408,910 common shares under Rule 144. The shares have an aggregate market value of $1,113,038.00, with an approximate sale date of February 10, 2026 on the NASDAQ exchange.

The seller previously acquired these common shares in Series A financing transactions from Tenaya Therapeutics on October 13, 2016 and July 31, 2017, paying the purchase price in cash. The person signing the notice represents that they are not aware of undisclosed material adverse information about Tenaya’s operations.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for TNYA disclose?

The Form 144 for TNYA discloses a stockholder’s intention to sell 1,408,910 common shares of Tenaya Therapeutics under Rule 144. It outlines share quantity, market value, acquisition details, planned sale date, and trading venue.

How many Tenaya Therapeutics (TNYA) shares are planned for sale?

The filing states that 1,408,910 common shares of Tenaya Therapeutics are proposed to be sold. These shares relate to a previously acquired position and represent a specific block the stockholder intends to sell under Rule 144 conditions.

What is the aggregate market value of the TNYA shares to be sold?

The proposed sale of Tenaya Therapeutics shares has an aggregate market value of $1,113,038.00. This value reflects the filer’s calculation for the 1,408,910 common shares covered by the notice at the time of preparing the Form 144.

When might the Tenaya Therapeutics (TNYA) Rule 144 sale occur?

The notice lists an approximate sale date of February 10, 2026. This date indicates when the stockholder expects to begin selling the 1,408,910 Tenaya Therapeutics common shares described in the Form 144 on the NASDAQ exchange.

How were the TNYA shares in this Form 144 originally acquired?

The shares were acquired in Series A financing transactions from Tenaya Therapeutics on October 13, 2016 and July 31, 2017. The Form 144 notes that the purchase price for these common shares was paid entirely in cash.

On which exchange will the Tenaya Therapeutics (TNYA) shares be sold?

The Form 144 indicates that the NASDAQ exchange is the trading venue for the planned sale. The 1,408,910 Tenaya Therapeutics common shares are expected to be sold through a broker, BTIG, LLC, in transactions executed on NASDAQ.

What representation does the seller make in the TNYA Form 144?

The person for whose account the securities will be sold represents that they do not know any undisclosed material adverse information about Tenaya Therapeutics’ current or prospective operations at the time of signing the notice.
Tenaya Therapeutics, Inc.

NASDAQ:TNYA

TNYA Rankings

TNYA Latest News

TNYA Latest SEC Filings

TNYA Stock Data

182.08M
215.09M
0.7%
22.21%
8.55%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO